These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 28649058)
21. [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder]. Zhang HY; Du ML; Zhuang SQ; Liu MN Zhonghua Er Ke Za Zhi; 2005 Oct; 43(10):723-7. PubMed ID: 16255846 [TBL] [Abstract][Full Text] [Related]
22. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder. Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111 [TBL] [Abstract][Full Text] [Related]
23. Effects of buspirone on operant and nonoperant food intake in food deprived rats. Ebenezer IS Methods Find Exp Clin Pharmacol; 1996 Sep; 18(7):475-80. PubMed ID: 8900221 [TBL] [Abstract][Full Text] [Related]
24. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143 [TBL] [Abstract][Full Text] [Related]
25. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731 [TBL] [Abstract][Full Text] [Related]
26. Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Kleven M; Prinssen EP; Koek W Eur J Pharmacol; 1996 Oct; 313(1-2):25-34. PubMed ID: 8905325 [TBL] [Abstract][Full Text] [Related]
28. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate]. Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201 [TBL] [Abstract][Full Text] [Related]
29. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856 [TBL] [Abstract][Full Text] [Related]
30. A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior. Thanos PK; Robison LS; Steier J; Hwang YF; Cooper T; Swanson JM; Komatsu DE; Hadjiargyrou M; Volkow ND Pharmacol Biochem Behav; 2015 Apr; 131():143-53. PubMed ID: 25641666 [TBL] [Abstract][Full Text] [Related]
32. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084 [TBL] [Abstract][Full Text] [Related]
33. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Haleem DJ; Shireen E; Haleem MA Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1323-9. PubMed ID: 15588759 [TBL] [Abstract][Full Text] [Related]
34. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover. Ballarín M; Carceller A; Guitart X Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571 [TBL] [Abstract][Full Text] [Related]
35. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Lakić A Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377 [TBL] [Abstract][Full Text] [Related]
36. Cognitive Improvement of Attention and Inhibition in the Late Afternoon in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Treated With Osmotic-Release Oral System Methylphenidate. Slama H; Fery P; Verheulpen D; Vanzeveren N; Van Bogaert P J Child Neurol; 2015 Jul; 30(8):1000-9. PubMed ID: 25296928 [TBL] [Abstract][Full Text] [Related]
37. Repeated administration of methylphenidate produces reinforcement and downregulates 5-HT-1A receptor expression in the nucleus accumbens. Salman T; Nawaz S; Waraich RS; Haleem DJ Life Sci; 2019 Feb; 218():139-146. PubMed ID: 30594665 [TBL] [Abstract][Full Text] [Related]
38. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Routledge C; Gurling J; Ashworth-Preece MA; Dourish CT Eur J Pharmacol; 1995 Apr; 276(3):281-4. PubMed ID: 7601215 [TBL] [Abstract][Full Text] [Related]
39. Haloperidol attenuates Methylphenidate and Modafinil induced behavioural sensitization and cognitive enhancement. Alam N; Choudhary K Metab Brain Dis; 2018 Jun; 33(3):893-906. PubMed ID: 29470766 [TBL] [Abstract][Full Text] [Related]
40. Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder. Baskin BM; Dwoskin LP; Kantak KM Pharmacol Biochem Behav; 2015 Apr; 131():51-6. PubMed ID: 25643872 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]